[xoo_el_inline_form active="login"]
賽昂產線
Armed-T™ Platform could develop more than 50 types of therapies
Unlocking Limitless Potential with CytoArm’s Armed-T™ Platform
Our Armed-T™ pipeline features a range of therapies that are in various stages of development,
Reflecting our Armed-T™ Platform could develop limitless innovative treatments to patients in need.
CTA-002：轉移性結直腸癌 [點擊觀看YouTube影片]👈
我們的指標產品 CTA-002, features EGFR Armed-T™ cells designed to treat metastatic colorectal cancer by targeting the EGFR receptor. This therapy is currently under IND application in both Singapore and the U.S. CTA-002 有望成為 EGFR 表達實體腫瘤患者的突破性治療選擇，顯著提高存活率並改善生活品質。未來擴展可能包括其他 EGFR 表達的癌症，例如 (三陰性乳腺癌 Click to watch videos on YouTube)👈.
CTA-003：前列腺腺癌
CTA-03 involves the development of PSMA Armed-T™ cells targeting prostate adenocarcinoma, one of the most prevalent cancers among men. Now in the discovery phase, our research is focused on optimizing this therapy’s design and evaluating its therapeutic potential to meet the critical needs in prostate cancer treatment.
CTA-004：轉移性乳腺癌
CTA-04 leverages HER-2 Armed-T™ cells in the fight against metastatic breast carcinoma, an aggressive and challenging cancer type. Our ongoing research aims to create a treatment that not only manages but potentially reduces the spread of metastatic breast cancer, bringing renewed hope to patients with this condition.
賽昂合作開發產線
Chinese 
English